Truvestments Capital LLC Invests $41,000 in Clorox Co (CLX)

Share on StockTwits

Truvestments Capital LLC acquired a new stake in Clorox Co (NYSE:CLX) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 255 shares of the company’s stock, valued at approximately $41,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund boosted its position in shares of Clorox by 48,033.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,808,980 shares of the company’s stock valued at $44,000 after purchasing an additional 6,794,834 shares during the period. Morgan Stanley boosted its position in shares of Clorox by 178.2% in the 3rd quarter. Morgan Stanley now owns 3,063,813 shares of the company’s stock valued at $460,828,000 after purchasing an additional 1,962,433 shares during the period. Norges Bank acquired a new stake in shares of Clorox in the 4th quarter valued at about $175,485,000. BlackRock Inc. boosted its position in shares of Clorox by 7.7% in the 4th quarter. BlackRock Inc. now owns 10,555,837 shares of the company’s stock valued at $1,627,074,000 after purchasing an additional 752,085 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Clorox by 21.5% in the 4th quarter. Geode Capital Management LLC now owns 1,899,544 shares of the company’s stock valued at $292,347,000 after purchasing an additional 335,835 shares during the period. Institutional investors and hedge funds own 76.90% of the company’s stock.

Clorox stock opened at $152.34 on Wednesday. Clorox Co has a twelve month low of $113.57 and a twelve month high of $167.70. The company has a quick ratio of 0.66, a current ratio of 1.15 and a debt-to-equity ratio of 3.08. The company has a market cap of $19.79 billion, a price-to-earnings ratio of 24.34, a P/E/G ratio of 3.86 and a beta of 0.32.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Monday, February 4th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.32 by $0.08. Clorox had a return on equity of 105.97% and a net margin of 12.65%. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.47 billion. During the same period last year, the firm earned $1.77 EPS. The firm’s revenue for the quarter was up 4.0% on a year-over-year basis. As a group, research analysts forecast that Clorox Co will post 6.31 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Wednesday, April 24th will be given a dividend of $0.96 per share. The ex-dividend date is Tuesday, April 23rd. This represents a $3.84 dividend on an annualized basis and a yield of 2.52%. Clorox’s payout ratio is 61.34%.

CLX has been the subject of a number of research analyst reports. Zacks Investment Research raised Clorox from a “hold” rating to a “buy” rating and set a $177.00 target price for the company in a research report on Monday, March 11th. BMO Capital Markets set a $175.00 target price on Clorox and gave the company a “buy” rating in a research report on Tuesday, February 5th. Wells Fargo & Co reissued a “hold” rating and issued a $157.00 target price on shares of Clorox in a research report on Monday, February 4th. Barclays reissued a “hold” rating and issued a $142.00 target price on shares of Clorox in a research report on Wednesday, February 6th. Finally, Citigroup set a $171.00 target price on Clorox and gave the company a “hold” rating in a research report on Tuesday, February 5th. Six research analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $151.21.

In other news, SVP Matthew T. Laszlo sold 10,585 shares of the firm’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $153.89, for a total value of $1,628,925.65. Following the completion of the sale, the senior vice president now directly owns 17,994 shares of the company’s stock, valued at approximately $2,769,096.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Andrew J. Mowery sold 5,340 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $156.44, for a total value of $835,389.60. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.

WARNING: This article was originally reported by Fairfield Current and is owned by of Fairfield Current. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.fairfieldcurrent.com/news/2019/04/17/truvestments-capital-llc-invests-41000-in-clorox-co-clx.html.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Article: Trading signals using Bollinger bands

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply